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Fixation of the urinary sediment for the diagnosis of hematuria. BE.
van der Snoek and RAP. Koene, Department of Nephrology, University
Hospital Nijmegen, Nijmegen, The Netherlands. For a reliable interpreta-
tion of the urinary sediment, a freshly voided urine sample is required to
avoid changes of the cellular morphology and the disappearance of cells
and casts. This is especially a problem in patients with unexplained
hematuria. Methods for fixation of the urinary sediment have so far
proved unsatisfactory. We found that using Cell-FIX', a formaldehyde-
based fixation reagent, it was possible to conserve all elements in the
sediment. To validate this finding, we have performed a systematic study
in which sediments from freshly voided urines were compared with fixed
sediments prepared from the same sample. Forty-six patients who had
been referred by their general practitioner to the urology clinic because of
unexplained, isolated hematuria were included in the study. The urinary
sediment was examined by an experienced nephrologist within 3 hours
after voiding. Four drops of a second sample (about 0.2 ml) were put into
a small (2 ml) plastic vial containing 0.2 ml of Cell-FIX solution. This
sample was stored at room temperature and examined after 7—10 days by
the same observer, together with 2 sediments from other patients with
hematuria to avoid recognition of the previously examined fresh sample.
The percentage of dysmorphic erythrocytes was assessed by scoring 100
cells. Subsequently, the preparation was screened for the presence of
erythrocyte casts. Based on the combined findings a final diagnosis of
glomerular or non-glomerular hematuria was made. Thirty-four of the
fixed samples were independently scored by a second observer to assess
inter-observer variation. There was a highly significant correlation be-
tween the percentage of dysmorphic erythrocytes in the fresh and fixed
samples (r = 0.87, P < 0.0001) and between the scores of both observers(r = 0.92, P < 0.0001). When plotting the mean percentual scores of
dysmorphic erythrocytes in the fresh and fixed sediments against their
difference, the mean difference (± SD) was +2.8 10.4%. For the two
observers this mean was —2.2 7.6%. Neither mean differed significantly
from zero. Of the 22 sediments scored as glomerular in the fresh sample
only 3 were scored differently in the fixed sample (2 non-glomerular, 1
equivocal). None of the 20 non-glomerular diagnoses was scored differ-
ently. Four sediments were scored as "equivocal/repeat" in both samples
(observed agreement 94%, kappa 0.90). There was complete agreement
between the two observers with regard to the final diagnoses of all 34 fixed
sediments (kappa 1.0). Fixation of the urinary sediment with Cell-FlX'
does not lead to deformation of erythrocytes or to disappearance of casts
after storage for up to 10 days. The small vials can easily be mailed. This
will enable general practitioners to consult a specialist and may thus help
to avoid wrong referrals.
Thin GBM nephropathy: Premature glomerular obsolescence is asso-
ciated with hypertension and late onset renal failure. C.M.G. Nieuwhof F.
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de Heer, P. de Leeuw, and P.J. C. van Breda Vriesman, Maastricht, The
Netherlands. Thin glomerular basement membrane (GBM) nephropathy,
also called familial benign hematuria, is characterized by chronic hema-
tuna and uniform thinning of the lamina densa of the glomerular
basement membrane. It generally holds an excellent renal prognosis.
Alport syndrome in early stages can also show attenuation of the GBM;
conversely, renal insufficiency has been reported in familial benign hema-
tuna. In order to discern early Alport syndrome from thin GBM nephrop-
athy, we carried out a prospective epidemiological study in which 19
normotensive and non-azotemic adult patients with chronic microscopic
(18 of 19) and macroscopic (1 of 19) hematuria and biopsy-proven thin
GBM nephropathy were followed for a median of 12 years, range 9 to 15
years. Renal biopsies of thin GBM patients at entry showed an increased
incidence of focal global glomerulosclerosis when compared to disease
controls as IgA nephropathy (P = 0.047) and normal renal tissue (P =
0.075). All renal biopsies showed presence of the Goodpasture antigen
when tested immunohistoehemically. Presence of Alport syndrome was
excluded clinically as none of the patients had complaints of hearing loss
or abnormalities by audiography and ophthalmology. At the end of
follow-up, the incidence of hypertension in thin GBM nephropathy (35%)
exceeded that of healthy clinical controls (P = 0.048), and one of the
hypertensives developed mild renal failure. In the normotensive patients,
the glomerular filtration rate at follow-up as measured by inulin clearance,
was reduced in three out of 7; these were over 50 years of age. Although
no family members were known to have renal disease at inclusion, within
four families, six elderly first-degree relatives had developed unexplained
renal insufficiency at the end of follow-up. Thus, thin GBM nephropathy
predisposes to premature glomerular obsolescence, leading in time to
increased incidences of hypertension and late onset renal insufficiency.
Renal arteriography: not a 24-carat gold standard for renal artery
stenosis. B.C. van Jaarsveld, P. Krijnen, L.C. van DijIç, H. Pieterinan, A.J.
van Seijen, FH.M. Derkc, A.i Man in 't Veld, and MA.D.H. Schalekamp,
on he ha If of the DRASTIC Investigators Group, Rotterdam, The Netherlands.
Renal arteriography is considered to be the gold standard for diagnosing
renal artery stenosis. However, the exact degree of stenosis at which blood
flow becomes impaired and renin-mediated hypertension ensues, is a
much debated issue. There is also no answer to the question of whether
lesions located in the ostial segment of the renal artery can be successfully
dilated by balloon angioplasty. It is therefore essential to know how
radiologists agree in their assessment of the X-ray images. Patients
participating in a multicentre study on renovascular hypertension, under-
went renal arteriography when their hypertension was resistant to a
two-drug regimen. All arteriograms were blinded for patient and hospital
characteristics, and were separately assessed by 3 experienced radiologists.
No prearrangements were made regarding diagnostic characteristics and
criteria. They were asked to report on (1) the number of renal arteries per
kidney, (2) presence and location of stenosis (ostial, proximal, middle or
distal part of renal artery), (3) type of stenosis (concentric or eccentric,
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with or without poststenotic dilation, string of beads appearance), and (4)
severity of stenosis (categories of 10% diameter reduction). Kappa values
(K) between the radiologists (A-B, A-C and B-C) were calculated as a
measure of interobserver agreement. A total of 254 arteriograms of 237
patients (53.1 12.2 years, 132 M, 253 right and 254 left kidneys) were
assessed. The radiologists reported 1 renal artely in 86.7—88.3%, 2 renal
arteries in 10.9—12.5%, and  3 renal arteries in 0.4—1.2% of the right
kidneys (K 0.62—0.69). For the left kidneys these values were 86.5—93.0%
for 1, 6.1—12.7% for 2, and 0.4—0.8% for  3 renal arteries (K 0.41—0.74).
On the condition of agreement about the number of renal arteries, a
stenosis was seen in 18—26% of 220 right kidneys (K 0.75—0.82) and in
24—29% of 212 left kidneys (K 0.84—0.85). Overall, one or more stenoses
of  50% diameter reduction were seen in 31—35% of the arteriograms
(K 0.80—0.85). When the analysis was limited to the kidneys in which all 3
radiologists observed a stenosis (whatever its degree) in the major artery,
most of the lesions were reported in the proximal part of the artery
(51—79%), but agreement on location was poor (weighed K 0.31—0.52).
Description of the type of stenosis was identical in only 29—45% of the
kidneys. There was agreement on the exact percentage of diameter
reduction in 35—44% of the kidneys (weighed K 0.56—0.62). In conclusion,
interobserver agreement was satisfactory for the question stenosis versus
no stenosis, and < 50% versus  50% stenosis. Concordance was poor for
the assessment of the degree of stenosis, its location and the type of lesion.
Judgment of arteriographic results is less uniform than one would wish for
a so-called gold standard.
Aspirin renography and captopril renography for the detection of renal
artery stenosis. PiG van de Ven, JMH de Kierk, FJA Beek, PP van Rzjk,
WPT/IM Mali, HA Koomans, and JJ Beutle,; Departments of Nephrology and
Hypertension, Radiology and Nuclear Medicine, University Hospital Utrecht,
Utrecht, The Netherlands. The present study was designed to compare the
diagnostic accuracy of aspirin renography (A-reno) and captopril renog-
raphy (C-reno) to detect renal artery stenosis in hypertensive patients.
Seventy-five patients with clinical clues suggestive of renovascular hyper-
tension underwent A-reno, C-reno and intra-arterial subtraction angiog-
raphy (DSA). The patients received captopril 25 mg and aspirin 20 mg/kg
1 hour before the respective studies. Renal scintigrams were performed
using 9smTcMAG3 and were evaluated according to the consensus
criteria of Nally et at. A RAS was defined as  50% stenosis on DSA.
Fifty-one patients had renal artery stenosis on DSA (34 unilateral, and 17
bilateral).
N
Aspirin-renography Captopril-renography
positive negative positive negative
RAS 51 42 9 41 10
NoRAS 24 4 20 7 17
The sensitivity of aspirin and captopril renography was 82% and 80% and
the specificity 83% and 71%, respectively (not significant). In conclusion,
aspirin renography is as good as captopril renography in the detection of
renal artery stenosis in a hypertensive population suspected for renovas-
cular disease.
Vasopressin regulation of transcellular water flow in MDCK cells
stably-translècted with aqua porin-2. P.M. T. L)een, J.P.L. Ri/ss, SM. Mul-
ders, R. Bindels, and C.H. van Os, Department of Cell Physiology, University
of Nijmegen, The Netherlands. In principal cells of the renal collecting duct,
reabsorption of water is accomplished by vasopressin-induced insertion of
aquaporin-2 (AQP2) water channels into the apical membrane, while
subsequent endocytosis of AQP2 molecules restores the water-imperme-
able state. Mutations in the AQP2 gene have been shown to cause the
autosomal form of nephrogenic diabetes insipidus (NDI). Expressed in
Xenopus oocytes, all missense AQP2 mutants, encoded in ND!, appeared
to be impaired in their transport to the plasma membrane. These cells,
however, have no vasopretsin-V2 receptor, are not polarized and do not
shuttle AQP2. Madin-Darhy canine kidney (MDCK) type I cells express
the V2-receptor and are polarized. In order to characterize whether these
cells can constitute a good in vitro cell system to study vasopressin-
regulated AQP2-mediated transeellular water permeability, these cells
were stably transfeeted with an AQP2 expression construct. A represen-
tative clone (WT1O), with a high expression level of AQP2, was selected.
After growing to confluency on semipermeable supports, WT1O cells were
subjected to an osmotic gradient and transeellular osmotic water perme-
ability (Pf; in sm/s SEM) was measured. In the absence of dDAVP the
Pf was 10.6 0.8, while addition of dDAVP revealed a Pf of 35.7 1.2.
The Pf of untransfected cells was 6.5 0.8 and was unchanged by dDAVP.
Fixation with 1% glutaraldehyde stabilized the basal and dDA VP-elevated
Pf of WT1O cells, offering the opportunity to study the kinetics of Pf
induction. Fixation after dDAVP addition revealed that maximal Pf was
obtained within 30 mm and remained elevated for at least 2 hrs.
Intracellular cAMP levels peaked within 5 mm after dDAVP admission
and decreased to basal levels within 30 mm. Pre-incubation with dDAVP
for 30 mm followed by washout of dDAVP and fixation indicated that the
Pf already decreased within 15 mm and returned to basal levels within 75
mm. Confocal laser scanning microscopy of dDAVP-treated WT1O cells
revealed a clear apical staining of AQP2, in contrast to a more scattered
staining in non-stimulated WT1O cells. In conclusion, an in vitro cell model
was generated, in which the regulation of transcellular water transport can
be studied in detail. In addition, by studying AQP2 mutants in these cells,
the molecular cause underlying ND! can defined in cells that closely
mimicks the routing and vasopressin-regulated shuttling of AQP2 as found
in principal cells.
Intracellular Na levels during Na reabsorption in rabbit cortical
collecting system. A. Hartog, A.M. T. Engbersen, A. van Pelt, C.H. van Os,
and R.J.M. Bindels, Department of Cell Physiology, University of Nijmegen,
The Netherlands. Na reabsorption by the collecting duct is a two-step
process: entry via a benzamil-sensitive Na channel and exit via an
ouabain-sensitive Na-K-ATPase. Both transporters must be tightly
regulated in order to maintain low intracellular Na levels ([NaI1) during
transcellular Na transport. In this study, [Na] was measured with the
fluorescent probe SBFI during variation of the Na transport rate in
rabbit connecting and cortical collecting tubules (referred to as cortical
collecting system) cultured on permeable supports. Active Na transport
was estimated as the benzamil-sensitive short-circuit current in an Ussing
chamber. Inhibition of Na transport by benzamil (10 M, apical side)
decreased [Na] from 7.6 0.9 to 5.1 0.4 mtvi (P < 0.001). Similar
results were obtained by removal of Na from the apical compartment,
indicating that influx of Na occurs primarily via benzamil-sensitive Na
channels. Suppression of ion transport by ouabain (10 M) increased
[NaI1 above 60 m, but in the presence of benzamil [NaI1 only increased
to 15.5 0.9 mat. Aldosterone (15 hr, iO u) stimulated active Na
transport by 125 11%. This increase was paralleled by a higher set point
in [NaI (9.0 0.6 vs. 13.2 0.6 m for control and aldosterone-treated
cells, respectively, P < 0.001). Finally, the basolateral compartment was
perfused with Na-free medium to inhibit the Na-Ca2 exchanger. This
reduced Na] by 4.9 0.5 mat and increased [Ca211, while Na
transport was stimulated by 80%. In conclusion, [Na11 is maintained
within a narrow range during large variations in transcellular Na
transport in rabbit cortical collecting system.
Mutations in the inwardly-rectifiing renal potassium channel (ROMK)
cause the antenatal variant of Bartter syndrome. H.H. Lemmink,
N.A. V.M. Knoers, R.J. Bindels, W.N. Nillesen, M. Kansen, A. van der Kemp,
LA.!-!. Monnens, and L.P. W.J. van den Heuve4 Departments of Pediatrics,
Cell Physiology and Human Genetics, University Hospital Nijmegen, Nijme-
gen, The Netherlands; C. Antignac, INSERM U423, Hospital Necker, D.
Feldmann, Hospital Anna,id- Trousseau, Paris, France; F. Hildebrandt
Department of Pediatrics, University Freihurg, H. W. Seyherth, Department of
Pediatrics, Marburg, Germany; and L. Guay- Woodford, Birmingham, Ala-
bama, USA. Bartter's syndrome (BS) is an hereditary, renal tubular
disorder primarily characterized by hypokalaemic metabolic alkalosis. BS
can he clinically subdivided into at least two phenotypes; (1) classical and
(2) neonatal variants of Bartter's syndrome. Recent studies have demon-
strated six different mutations in the Na-K-2C1 cotransporter (NKCC2)
gene in live neonatal BS patients (Nature Genet 13:183—188, 1996). In
some neonatal Bartter families the involvement of the NKCC2 gene could
be excluded which prompted the search for mutations in regulators of
NKCC2 cotransporter activity. One regulator is the ATP-sensitive potas-
sium channel (ROMK). We have identified eleven different mutations in
the ROMK gene that cosegregate with the neonatal BS phenotype. The
defects involved substitutions of amino acid residues conserved through
evolution or were part of functionally important domains. Two mutations
introduced frameshifts or premature stopcodons and were predicted to
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result in truncated potassium channel proteins. We are currently studying
the functional effect of individual mutations by voltage clamp analysis of
Xenopus oocytes after injection with wildtype and mutant ROMK cRNA.
Our findings indicate that antenatal Bartter syndrome is genetically
heterogenous and provides further insight into the molecular pathophys-
iology of Bartter-like disorders.
Phosphate resorption after ingestion in vegetable versus animal food.
I.H. Go, J. Dommerholt, M. Schuurmans, Canisius Wilhelmina Hospital
Ntjmegen, The Netherlands. Phosphate restriction in diets in end-stage
renal disease is essential to prevent hyperphosphate, secondary hyperpara-
thyroidism and calcium-phosphate disposition in soft tissues. In the
literature it is postulated that phosphate in vegetables is bound as phytate
and for that reason cannot be resorbed as well as phosphate from an
animal origin. If this assumption is true, nutritious foods such as whole-
meal bread, nuts and many vegetables could be admitted free to the diet
and need not to be combined with phosphate binding medication. We
studied the daily urinary excretion of phosphate (P) in healthy volunteers,
5 men and 5 women, who ingested about 1460 milligrams of P in two
periods of four days. The periods were fourteen days apart. In the first
period half of the volunteers used a vegetarian diet, which still contained
19 mg of animal P; the other half used a diet containing meat and dairy
products, which still contained 285 mg of vegetable P. In the second period
the two groups of volunteers used the other diet. Urine was collected in 24
hours during the last three days of each period. The results indicated a
significant difference between the urinary P-excretion in humans using an
animal or a vegetable diet: on the third day respectively 57.2 and 46.9%,
on the fourth day 57,3 and 44% of the P ingested was excreted. The
differences () in the mean P-excretion between the animal and vegetable
diets, given in percentages of the total P-ingestion of the third and fourth
days are given in the Table:
Conf.
Day % interval. P
mean P urinary excretion 3 10.3 1.7—18.9 0.024
(in % of P-ingestion) 4 13.2 5.9—20.5 0.003
one sample mean T-test
The mean resorption of P intake in vegetable food was much less than of
P in animal food. In clinical practice it is more probable that vegetable
food can be accompanied with much less P-binding medication than when
animal P is ingested. The P-resorption in uremic patients will be investi-
gated.
Drug targeting to the urinary tract: An increased urinary excretion and
reduced renal toxicity of doxorubicin. M. Haas, A. Elsinga, A. T Tiebosch,
CA. Kiuppel, P.E. de Jong, D.KF. Metier, F. Moolenaar, D. de Zeeuw,
GIDS, University of Groningen, The Netherlands. Drug targeting to the
urinary tract may be of interest for drugs with a low degree of urinary
excretion or a high systemic or renal toxicity. In the present study,
doxorubicine (doxo) was coupled via a spacer to the low-molecular-weight
protein, lysozyme. Circulating native lysozyme is predominantly reab-
sorbed from the lumen into the proximal tubular cell of the kidney
followed by lysosomal degradation. Since the reabsorption process re-
quires positively charged groups in the protein, we hypothesized that
masking the positively charged amino-groups of lysozyme with doxo-
spacer molecules may result in a predominant excretion into the urine. A
doxo-lysozyme conjugate was synthesized with an average coupling degree
of 6.3 mole doxo to 1 mole of lysozyme. Urinary excretion and renal
toxicity of the conjugate was studied in the rat in comparison with free
doxo. Male Wistar rats were injected intravenously with a single dose of
either 2 mg/kg free doxo (N = 5) or equimolar amounts of doxo-lysozyme(N = 6). Conjugation to lysozyme resulted in a marked increase in the
total amount of doxo excreted in the urine (28 3 vs. 4 2% of the dose
in the first 24 hours after injection). In the rat, especially the kidneys are
sensitive to doxo, a phenomenon also known as the adriamycin model of
experimental nephropathy. During the 16 weeks follow-up, the rats that
had received free doxo developed pronounced glomerular disease indi-
cated by a proteinuria of 340 22 mg/day and glomerular sclerosis. None
of the rats injected with the doxo-lysozyme conjugate showed any of such
toxicity (14 3 mg protein/day, no sclerosis). In conclusion, doxorubicine
can be targeted to the urinary space by coupling to the low-molecular
weight protein lysozyme. Conjugation to lysozyme increases the urinary
excretion of doxo and prevents the renal toxicity of the drug. Obviously,
for an anti-tumor effect in the urinary space, the doxo has to be released
from the conjugate. For this purpose, the pH-sensitive cis-aconityl spacer
was used to link doxo to lysozyme, a bond that can be hydrolyzed in
acidified urine.
The endothelin system is involved in the effects of chronic NOS
inhibition. A.MG. J/erhagen, J.A. Joles, T.J. Rabelink B. Braam, H.J.
Gröne, and HA. Koomans, Department of Nephrology, University Hospital
Utrecht, Utrecht, The Netherlands and Department of Pathology, Philipps
University of Marburg, Germany. Chronic nitric oxide synthase (NOS)
inhibition leads to hypertension, renal vasoconstriction, left ventricle
hypertrophy, a decrease in glomerular filtration rate (GFR) and renal
blood flow, proteinuria and renal morphological changes. During chronic
NOS inhibition, continuous angiotensin II blockade ameliorates hyperten-
sion and renal dysfunction, and blunts or prevents the arteriolar and
glomerular injury and cardiac hypertrophy. However, not much is known
about the effects of endothelin blockade on chronic NOS inhibition.
Because NO inhibits the synthesis and antagonizes the vasoconstrictor
effects of endothelin, inhibition of NO synthesis might unmask vasopres-
sor effects of endothelin. We blocked the ETA receptor during chronic
NOS inhibition with A-127722. Male Sprague-Dawley rats (200 g), 8
rats/group, were studied for 3 weeks: group 1, control (normal chow and
water); group 2, nitro-L-arginine (NLA) (40 mg/kg/day); group 3, NLA
(40 mg/kg/day) + A-127722 (30 mg/kg/day). Every week, systolic blood
pressure (SBP) and proteinuria were measured. After 3 weeks, GFR, body
weight, kidney weight, heart weight (HW) and histology were evaluated
(Table).
Control NLA
NLA +
A-127722
SBPmm Hg
Proteinuria mg/day
160 726 3 240 6209 46 19139 8b
GFR mI/mm 2.23 0.019 1.57 0.22 1.98 0.16
HW/100 g body wt 0.315 0.008 0.439 0.018 0.340 0.014
Data are mean SEM. a P < 0.05 vs. control, P < 0.05 vs. NLA
(ANOVA)
NLA resulted in a severe rise in blood pressure and proteinuria, a
decrease in body weight and GFR and an increase in heart weight index.
Glomeruli showed severe ischemia, some protein drops, thrombosis and
necrosis. There was severe vessel wall damage, thrombosis and moderate
tubulointerstitial damage; 80% of the rats showed heart infarcts. A-127722
administered concomitantly with NLA gave complete protection from
proteinuria, but no protection on protein droplets in the glomerulus.
Blood pressure, GFR and heart weight index were intermediate between
control and NLA. There was complete protection on thrombosis, ischemia
and necrosis in the glomeruli. There was partial protection on tubuloin-
terstitial damage and vessel wall damage and complete protection on
thrombosis. There was little effect on heart infarcts. ETA receptor
blockade could partly prevent the effects of chronic NOS inhibition. This
suggests that besides the renin-angiotensin system the endothelin system is
also involved in the effects of chronic NOS inhibition.
Expression of iNOS, eNOS, and peroxynitrite modified proteins in
experimental anti-myeloperoxidase associated crescentic glomerutone-
phritis (NCGN). P. Heeringa, H. van Goor, H. Moshage, PA. Klok and
C. G.M. Kallenberg Departments of Clinical Immunology, Pathology, and
Division of Gastroenterology and Hepatology, University Hospital Groningen,
Groningen, The Netherlands. Nitric oxide radicals (NO) are important
mediators of physiological and pathophysiological processes in the kidney.
N0 produced by the endothelial NO synthase isoform (eNOS) is a factor
mediating vasodilation and inhibiting platelet aggregation. Excessive
amounts of N0 produced by the inducible NOS (iNOS) in inflammatory
cells may, however, cause injury. N0 can react with superoxide anion
(O2) yielding peroxynitrite anions (PN: 0N00). PN may cause lipid
peroxidation or directly modify proteins by nitration of tyrosine residues
resulting in loss of function of proteins. To study the role of the NO
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radicals and superoxide anion in the development of acute glomerulone-
phritis, we examined the expression of iNOS, eNOS, O2, and PN
modified proteins in a rat model of antimyeloperoxidase (MPO) NCGN.
Rats were immunized with MPO in CFA. After two weeks, the left kidney
was perfused with a neutrophil lysosomal extract and H202. Rats were
sacrificed at 24 hours, 4 days, and 10 days after perfusion. Kidney slices
were stained by immunohistochemistry with antibodies directed against
macrophages (ED1), granulocytes (HIS 48), iNOS, eNOS, and PN. 02
radicals were visualized using the Briggs method. Marked influx of
macrophages and granulocytes was found in glomeruli and interstitium at
24 hr, increasing at 4 days, and decreasing at 10 days. Increased numbers
of O2 producing cells were found at all time points peaking at day 4.
iNOS was abundantly present in inflammatory cells at 24 hours and 4 days.
Surprisingly, inflammatory cells in the interstitium were largely negative
for iNOS at day 4. In control rats, strong staining for eNOS was found in
glomerular capillaries and interstitial tubular capillaries and larger vessels.
In experimental rats, glomerular eNOS staining was greatly reduced at 24
hours. At 4 days and 10 days, eNOS staining was absent in severely
damaged glomeruli. Immunoreactivity for PN modified proteins was
intense at 24 hours in a characteristic capillary staining pattern. At 4 days
and 10 days PN immunoreactivity was often found in a crescentic like
pattern, but was also observed periglomerular around Bowman's capsule.
In conclusion, in experimental anti-MPO associated NCGN iNOS is
expressed in the presence of O2 producing cells, whereas eNOS
expression is reduced. In addition, peroxynitrite modified proteins are
formed, suggesting that reactive oxygen species generated by NO syn-
thases and activated inflammatory cells may contribute to tissue injury in
experimental anti-MPO associated NCGN.
Co-deposition of polymeric IgA together with IgG in the rat glomerulus
results in an enhanced, complement-dependent renal inflammation.
M. G.A. Van Dishoorn, T Sato, Y Muizert, D.J. Van Gijlswijk-Janssen, E. De
Heer, M.R. Daha, Department of Nephrology and Pathology, University
Hospital Leiden, Leiden, The Netherlands. IgA nephropathy is the most
common type of immunologically mediated glomerulonephritis (GN) and
is characterized by glomerular deposition in the mesangium of mainly
polymeric IgA together with C3, C9 and Properdin. In patients co-
deposition of polymeric IgA together with tgG and/or 1gM can lead to a
more progressive development of disease. An experimental form of
mesangial proliferative GN can be induced in Wistar rats by mouse IgG2a
anti-Thyl.1 antibodies (ER4G). In contrast, administration of polymeric
mouse IgA anti-Thyl.1 antibodies (pER4A) to rats only results in
hematuria in the absence of detectable mesangial complement deposition.
To investigate the effect of the combination of ER4G and pER4A, a
suboptimal dose of ER4G (0.38 mg/kg) was infused in Wistar rats in the
presence of increasing concentrations of pER4A (1.0, 2.5 or 7.5 mg/kg).
Injection of ER4G alone to rats resulted in the induction of albuminuria
(4 0.3mg protein/24 hrs) and 4.4 1.5 macrophages per glomerulus on
day 1, whereas the exclusive deposition of pER4A was not accompanied by
a significant glomerular influx of monocytes nor activation of complement.
However, glomerular deposition of C6 and CSb-9 and the degree of
glomerular adhesion to Bowman's capsule was dramatically increased in
the combination groups. In addition, a significant (P < 0.02), dose
dependent, synergistic increase in albuminuria was found in urine of rats
receiving both antibodies as compared to rats treated with a single
antibody. Microhematuria did not differ between rats receiving either
pER4A, ER4G, or the combination. We conclude that in this model for
IgA ncphropathy a selective, complement dependent, synergistic inflam-
mation is induced in Wistar rats by glomerular co-deposition of mouse
anti-Thy 1.1 monoclonai antibodies.
TGFI3, but not angiotensin II, enhances matrix production by human
proximal tubular epithelial cells. C. van Kooten, A.M..T. Langer.s, ME.
Paape, N. Verhagen, MR. Daha, and L.A. van Es, Department of Nephrol-
ogy, Leiden University Hospital, Leiden, The Netherlands. Interstitial fibrosis
is the end stage of a common pathway of renal diseases, which is
characterized by excessive deposition of matrix components. In a previous
study, we have demonstrated that the deposition in the interstitial area of
collagen type IV (Coil IV) was found to be best associated with disease
progression. Since proximal tubular epithelial cells (PTEC) are a potential
source of these matrix components, and experiments with murine PTEC
have shown that angiotensin II (Ang II) enhances Coil IV production, we
studied the regulation of matrix production by in vitro cultured human
PTEC. To measure Coil IV and fibronectin (FN) in culture supernatants,
specific inhibition ELISA's were developed. The detection limit of these
assays was 15 ng/mi and 50 ng/ml, respectively. Without activation,
cultured PTEC produced significant amounts of both Coil IV (> 30 ng/ml)
and FN (> 150 ng/mI). Activation of PTEC with various doses of Ang II
(10-6 to 10 M) did not result in a significant increase in Coil IV or FN
production. However, strong enhancement of matrix production by human
PTEC was observed after activation with TGFI31. Activation with 10 ng/mi
of TGFPI resulted in a 2- to 4-fold enhancement of Coil IV production
and a 4- to 10-fold enhancement of FN production. RT-PCR analysis
showed that message for the COL4A1 could be detected in PTEC and that
this signal was increased after activation with TGFI31. In conclusion, we
showed that PTEC are an important source for various matrix proteins.
Under the circumstances used in our experiments, the production of these
matrix components was stimulated by TGFJ31, but not Ang II.
Persistently high levels of antibodies against myeloperoxidase (MPO)
are predictive of poor outcome in patients with anti-MPO associated
glomerulonephritis. C.F.M. Franssen, C.A. Stegeman, W. Oost-Kort,
C.G.M. Kallenberg, J. W Cohen Tervaert, Departments of Internal Medicine,
Divisions of Nephrology and Clinical Immunology, University Hospital
Groningen, The Netherlands. Patients with anti-MPO associated glomeru-
lonephritis are prone to develop progressive renal insufficiency despite an
initially favorable response to immunosuppressive treatment. This may be
due to persistent vaseulitie disease activity or to a process of scarring not
related to vaseuhtis. The aim of this study was to assess the value of
possibie prognostic parameters on renal outcome with the emphasis on
those parameters that reflect vasculitic disease activity. Therefore, we
analyzed the following parameters in 18 patients with biopsy-proven
anti-MPO associated giomeruionephritis who were followed for at least 2
years: renal biopsy characteristics, vaseulitis activity according to the
Birmingham Vasculitis Activity Score, cumulative prednisolone and cyclo-
phosphamide dose in the first year, C-reactive protein (CRP) levels, the
presence of persistent erythroeyturia (>10 red blood cells per high power
field) and anti-MPO levels by ELISA. Eight of 18 patients had a favorable
renal outcome, that is, no relapse or progressive renal insufficiency (group
A); five patients had one or more relapses (group B) and five patients had
progressive renal insufficiency (group C). At diagnosis, CRP levels,
anti-MPO levels, renal biopsy characteristics and vasculitis activity scores
did not differ between the three groups. In addition, the cumulative
prednisolone and cyciophosphamide dose in the first year did not differ. At
one year after diagnosis; however, anti-MPO levels had decreased signif-
icantly in group A (P = 0.02) and in group B (P = 0.02), but not in group
C (P = 0.34). Anti-MPO levels at one year were higher in patients who
relapsed or who had progressive renal insufficiency than in patients who
did well (P < 0.05). At one year, none of the patients in group A had
persistent erythrocyturia compared to one patient in group B and two
patients in group C (not significant). CRP levels at one year did not differ.
In conclusion, anti-MPO positive patients who develop progressive renal
insufficiency have persistently high anti-MPO levels suggestive of persis-
tent subclinical disease activity.
Sequential immunocytologic examination of urinary sediments in renal
transplant patients. Plz.M.M. Dooper, A.J. Hoitsma, RAP. Koene, M.J.J. T
Bagman, Departments of Pathology and Medicine, Division of Nephrology,
University Hospital Nijmegen, The Netherlands. Acute rejection (AR) of
renai aiiografts is accompanied with urinary T lymphocytosis and in-
creased HI.,A-DR expression on shedded tubular epithehai cells. Previ-
ously we reported that in the urine sediment these markers can he used to
discriminate AR from other causes of renal graft dysfunction. We now
tested whether sequential urinary immunocytologieai examination (UIC)
can be used as a reliable non-invasive method for monitoring AR. In a
large group of 121 unselected renal graft recipients we examined urinary
sediments, taken at reguiar intervais during the first six months after
transplantation, with frequencies from twice weekly gradually decreasing
to once monthiy in the last months. Cytospin preparations of the urinary
sediments were stained with conventional Papanicoiaou, and for U1C
incubated with antibodies against CD2 and HLA-DR, in a standard
indirect alkaline phosphatase technique. The presence of both T lympho-
cytosis and increased HLA-DR expression was considered consistent with
rejection (R), the presence of only one marker as probable rejection (PR).
Microscopic examination was blinded and retrospectively correlated with
clinical and histological data. Overall, the percentage of inadequate urine
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samples was 26%. Seventy-two of the 121 patients (59%) developed a
clinical AR, that was histologically confirmed in 52 cases. At the time of
AR adequate UIC was available in 57 of the 72 rejection episodes, and in
51 cases (90%) the UIC diagnosis was correct (38 X AR, 13 >< PR). In 3
of the 6 false-negative UIC diagnoses the concomitant renal core biopsy
showed acute vascular rejection without interstitial component. In 23 of 51
cases with clinical and cytological AR the UIC diagnosis preceded clinical
signs of AIR by 2—35 days [mean 11 2 (suM)]. In 49 stable patients who
did not develop clinical AR, UIC was positive in 345 of 1098 (3 1%, 143 X
AR, 202 X PR) samples. We conclude that the low incidence of
false-negative diagnoses makes UIC a sensitive method to rule out AR.
The high incidence of false-positive diagnoses is in accordance with
previously reported findings in sequential core biopsies. It limits the
diagnostic value of UIC, especially in the absence of clinical signs of
rejection.
Inhibition of the renin-angiotensin system (RAS) prevents and reduces
cerebral and renal lesions in the stroke-prone spontaneously hypertensive
rat (SHRSP). E.L.A. Blezer, M. Schurink, K Nicolay, HA. Koomans, and
J.A. Joles, Department of Nephrology, University Hospital Utrecht and
Department of In vivo NMR, Bijvoet Center, Utrecht University, The Neth-
erlands. With T2-weighted magnetic resonance imaging (T2MRI), we
evaluated the effects of different blockers of RAS at different time points
during the progression of malignant hypertension, on the manifestation of
cerebral edema and proteinuria in the salt loaded SHRSP. Male SHRSP
(8—10 weeks; N = 40) received 1% NaCI in tap water. T2MRI (25 coronal
slices >< 1 mm), U,V and systolic blood pressure (SBP) were determined
weekly in five groups: Group I (N = 6), control; group 2 (N = 8),
prophylactic treatment with enalapril (30 mg/day X kg) starts after an UV
level >40 mg/day (day 0); group 3 (N = 6), same as group 2 plus
treatment with losartan (60 mg/day x kg); group 4 (N = 9), therapeutic
treatment with enalapril after manifestation of cerebral edema (day OT);
group 5 (N = 9), same as group 4 with treatment with losartan. The
experiment was terminated when the animal was very debilitated or died
spontaneously. The percentage slices showing cerebral edema was calcu-
lated.
After
day °T/P Week 0 Week 1 Week 4
Prophylactic
U,V mg/day
Control
Enalapril
Losartan
77 1(6)
76 18 (8)
56 7(6)
107 35 (6)
52 9(8)
45 5(6)
222 56 (5)
76 10(7)
111 21(6)
Cerebral
edema %
Control
Enalapril
Losartan
0 00 00 0
9 80 00 0
30 9
1 I0 0
Therapeutic
UV mg/day
Control
Enalapril
Losartan
325 44 (6)
283 26(9)
266 33 (9)
231 45 (6)
116 21(8)
248 38 (9)
265 188 (2)
106 25 (8)
292 55 (9)
Cerebral
edema %
Control
Enalapril
Losartan
31 8
31 5
25 5
32 7
10 3
12 3
62 15 2
16 7
Week 32 Week 40 Week 48
Prophylactic
U,V mg/day
Control
Enalapril
Losartan
—
195 21(5)
127±20(6)
—
189 15 (4)
234(1)
—
—
436(1)
Cerebral
edema %
Control — — —
Week 32 Week 40 Week 48
Enalapril 0 0 0 0 —
Losartan 0±0 0±0 8
Therapeutic
UV mg/day
Control
Enalapril
Losartan
—
326 87 (4)
233 115 (3)
—
—
188 (1)
—
—
—
Cerebral
edema %
Control
Enalapril
Losartan
—
36 13
20 17
—
—
0 0
—
—
—
Data are mean SEM.
Day O was reached 17 to 34 days after start salt loading. Controls
developed severe proteinuria and cerebral edema whereas both treat-
ments substantially prolonged survival rate, delayed development of
proteinuria and prevented the formation of cerebral edema without
changes in SBP. At a later stage proteinuria develops without develop-
ment of cerebral edema. Day °T was reached 25 to 59 days after start salt
loading. In the controls U,V and cerebral edema severely progressed. As
a result of treatment survival rate substantially prolonged. UV decreased
in the enalapril treated and stabilized in the losartan treated group
whereas cerebral edema decreased with both treatments. Again SBP did
not decrease. During this stage an increasing activity of vasodilatory
substances is important. Eventually proteinuria and cerebral edema
reappear. In both starting points protection is not caused by a reduced
SBP, but is probably a direct consequence of the blockade of the vasotoxic
actions of angiotensin II in combination with a decreased vascular
permeability.
Verocytotoxin inhibits mitogenesis and protein synthesis in purified
human glomerular mesangial cells without affecting cell viability. Evi-
dence for two distinct pathways. PA. van Setten, V W.M van Hinsbeigh,
L.P. van den Heuvel, T.J. van der Velden, NC. van de Kar, and L.A.H.
Monnens, Department Pediatrics, University Hospital Nijmegen, Nijmegen,
and Gauhius Laboratory TNO-PG, Leiden, The Netherlands. Infection with
a verocytotoxin (VT) producing Escherichia coli has been strongly impli-
cated in the epidemic form of hemolytic uremic syndrome (HUS).
Endothelial damage in the glomeruli and arterioles of the kidney induced
by VT is believed to play a crucial role in the pathogenesis of HUS.
However, little information is available regarding the effects of VT on
mesangial cells, which also play an important role in glomerular function.
In this study we investigated the effects of VT on human mesangial cells
in vitro. Mesangial cells were enriched by collecting hillock-shaped out-
growths derived from human glomeruli, and subsequently purified by
elimination of contaminating epithelial cells by immunoseparation with
IJIex europeaus lectin-I-coated dynabeads. Their mesangial nature was
established by the presence of a-smooth muscle cell actin in highly
confluent cultures and the absence of cytokeratin or PECAM-1. Mesan-
gial cells bound VT to hands of globotriaosylceramide (Gb3) and a closely
related glycolipid, which is similar to a glycolipid involved in the VT-
dependent cytokine production in monocytes. VT did not induce the
release of cytokines or MCP-1 in mesangial cells. Binding of VT to Gb3
causes in VT susceptible cells cell death by inhibition of protein synthesis.
Although protein synthesis was inhibited in mesangial cells, all cells
remained viable, both under basal and TNFa-stimulated conditions.
Furthermore, VT markedly inhibited DNA synthesis and proliferation of
mesangial cells. The inhibition of mitogenesis was also found with the
B-subunit of VT-I alone, albeit to a lesser extent, without a significant
effect on protein synthesis. Because the inhibition of protein synthesis
involves the A-subunit, this suggests that two distinct pathways contribute
to the effects of VT on protein synthesis and mitogenesis in human
mcsangial cells.
Expression and function of Fas (CD95) on human renal tubular
epithelial cells. J. G. Boonstra, F.J. van der Woude, IC. Laterveer, P.C.
Wever, L.A. van Es, MR. Daha, and C. Van Kooten, Department of
Nephrology, Leiden University Hospital, Leiden, and Department of Nephrol-
ogy, Academic Medical Center, Amsterdam, The Netherlands. During renal
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allograft rejection, apoptosis can be found specifically in the tubular
epithelial cells, which are a main target during renal allograft rejection. A
potential route of apoptosis induction by alloreactive T cells might be the
interaction between Fas ligand on the activated T cell and Fas on the
target cell. Therefore, we studied whether tubular epithelial cells express
Fas and are sensitive to Fas-mediated apoptosis. We observed Fas
expression in Situ on epithelial cells of 50 to 70% of proximal and distal
tubuli in normal kidney sections. Cultured proximal tubular epithelial cells
(PTEC) expressed Fas, as shown by FACS (>95% positive cells) and
RT-PCR. To study the induction of apoptosis after Fas-ligation, Jurkat
cells and five primary PTEC lines were incubated for 18 hours in the
presence of agonistic anti-Fas antibodies, upon which the cells were
analyzed for apoptosis by nuclear staining. Cells with strongly condensed
and/or fragmented nuclei were considered apoptotic. Incubation with
anti-Fas resulted in > 80% apoptotie Jurkat cells, while no apoptotie
PTEC were observed. Fas is also described to transmit activation and
proliferation signals, but we could not observe any differences in cell
number or IL-8 production after Fas ligation on PTEC. However,
simultaneous treatment of PTEC with anti-Fas and cycloheximide (CHX)
resulted in a significant increase in the number of apoptotic cells up to
42.5 8.7% (P < 0.01). The induction of apoptosis with anti-Fas
antibodies and CHX was confirmed by the TUNEL method. We conclude
that Fas is present on renal tubular epithelial cells both in situ and in vitro,
but that these cells are resistant to Fas-mediated apoptosis under condi-
tions that do induce apoptosis in other cell types. Our data therefore
suggest that PTEC might have an active intracellular mechanism, which
protects them against Fas-mediated apoptosis.
The occurrence of soluble complement receptor 1 in urine of patients
with tupus nephritis and other glomerular diseases. C.E.H. Siegert, A.F.
Gerritsen, L.A. van Es, MR. Daha, Department of Nephrology, University
Hospital, Leiden, The Netherlands. Complement receptor 1 (CR1) is found
on glomerular epithelial cells. This receptor may play a role in controlling
local inflammation by the binding of its ligand (C3b) after activation of C3.
CR1 is composed of a transmembrane and a extracellular soluble part.
Soluble CR1, (sCR1) was detected by sandwich ELISA using mouse
monoclonal and rabbit polyclonal anti-sCR1 antibodies. Recombinant
sCR1 was used as a standard with concentrations ranging from 0 to 4.5
ng/ml. sCR1 levels were measured in paired urine and serum samples of
27 patients with systemic lupus erythematosus (SUE), 12 patients with IgA
nephropathy, 6 patients with idiopathic membranous nephropathy, and 25
healthy controls. Total proteinuria was also measured. Increased levels of
sCR1 could be demonstrated in urine of 11(41%) SLE patients, 2 (17%)
IgA nephropathy, and 4 (66%) idiopathic membranous nephropathy
patients. sCR1 could not be detected in urine of healthy individuals.
Serum sCR1 levels were in the same range in the patient groups and in
healthy individuals. In addition, urine sCR1 levels were not associated
with total proteinuria in the patient groups. SLE patients were classified as
active or inactive nephritis on the basis of histopathological criteria and
the presence of proteinuria or microscopic hematuria. Increased levels of
sCR1 were detected in the urine of 8 of 11 (73%) patients with active
nephritis and in the urine of 1 of 10 (10%) patients with inactive nephritis.
In both groups class III, IV, and V lupus nephritis were equally present.
The presence of increased levels of sCRI was not found to be restricted to
any specific lupus nephritis class. The presence of sCR1 in urine of several
glomerular diseases may reflect local complement activation. We conclude
that urine sCR1 levels may be a parameter of active lupus nephritis.
Strong expression of the TNF family member CD134(0X40)-ligand in
the glomerular capillary wall in proliferative lupus nephritis. A. Roos, N.
Claessen, ElM. Schilder-Tol, KIM Assmann, J. Shields, J.J. Weening and
J. Aten, Department of Pathology, Academic Medical Center, University of
Amsterdam, Department of Pathology, St. Radboud Hospital, University of
Nijmegen, and Cantab Pharmaceuticals, Cambridge, England, United King-
dom. Tn a model for systemic lupus erythematosus (SLE), induced by
HgCl2 in the BN rat, we found strongly increased expression of the TNF
receptor (TNFR) family member CD134 on CD4 T cells. Interaction
between TNFR relatives and their ligands (TNF family) is involved in
regulation of differential cell survival, activation, differentiation and death.
Abnormal expression of TNFa and CD4OL is correlated to disease activity
in patients with SLE. In the present study, we examined expression of
CD134 and its ligand (CD134L) in renal tissue from patients with: (a) SLE
with proliferative and non-proliferative forms of lupus nephritis (LN; N =
19); (b) idiopathic membranous glomerulopathy (MGP; N = 8); and (c)
urinary tract cancer (UTC; N = 9). Immunohistochemistry was performed
using a monoclonal antibody (mAb) anti-CD134, and a ehimeric molecule
containing the extracellular part of CD134 to detect CD134L. Variable
numbers of CD134 leukocytes were detected in renal infiltrates in 12 Out
of 19 SLE patients and in 5 out of 8 MGP patients, but only few positive
cells were found in renal interstitium in 3 out of 9 UTC patients.
Intraglomerular CD134 leukocytes were detected in 6 out of 13 patients
with type III or IV LN, in 1 out of 6 patients with other classes of LN, and
inS out of 6 MGP patients, but not in UTC patients. Detection of CD134L
revealed negative or faintly positive staining of renal parenchyma in UTC
patients. However, strong intraglomerular staining for CD134L, localized
in both subendothelial and subepithelial immune deposits, was observed
in 12 out of 13 patients with type III or IV LN, whereas 5 out of 6 SLE
patients with class II or class V LN showed slight mesangial staining. In 3
out of 6 MGP patients, faint CD134L staining of podocytes was detected;
subepithelial immune deposits were negative. From all pathological
entities examined thus far, types III and IV of LN are unique with respect
to CD134L staining of immune deposits. Analogous findings were ob-
tained in experimental models for several forms of immune-mediated
nephritis. Glomerulonephritides, occurring in aging MRL-lpr/lpr mice, in
mice undergoing a chronic semi-allogeneic graft-versus-host reaction, in
mice after injection of heterologous anti-GBM Ab, and in BN rats with
HgCl2-induced autoimmunity, were associated with increased glomerular
expression of CD134L. Glomeruli of mice that had received anti-amin-
opeptidase A or anti-dipeptidyl peptidase IV mAb, and, interestingly, also
of DZB rats with HgCl2-induced membranous nephropathy did not show
an overexpression of CD134L. The origin and the biochemical nature of
the glomerular CD134 ligand, as well as its pathophysiological relevance
remain to be elucidated.
Mercuric chloride induces T cell adhesion to fibronectin. A. Roos, M.
Neeft, ElM. Schilder-Tol, J.J. Weening, and J. Aten, Department of Pathol-
ogy, Academic Medical Center, University of Amsterdam, Amsterdam, The
Netherlands. Injection of HgCl2 into Brown Norway rats induces a systemic
autoimmunity, involving T and B cell activation, (auto-)antibody produc-
tion, multi-organ inflammation, glomerulonephritis and proteinuria. As
such, it serves as an animal model for drug-induced immune dysregulation
in humans. Lymphocyte activation in HgCI2-injected BN rats is accompa-
nied by up-regulation of T cell adhesion molecules, like LFA-l, ICAM-1
and a4 integrin. Inhibition of n4 integrin-mediated adhesion in vivo
prevents the major part of autoimmune manifestations induced by HgCI2.
Several divalent metal ions, like Mg2, Mn2, and Co2, have been shown
to activate binding of integrins to their ligands. We studied the effect of
HgCl2 on integrin-mediated T cell binding to fibronectin (FN), and the
mechanisms involved. Therefore, Jurkat T cells were incubated on FN-
coated wells, during one hour, in the presence or absence of HgCI2 or
other stimuli. After washing, bound T cells were quantified using a
DNA-binding fluorochrome. HgCl2 induced a dose-dependent T cell
binding to FN, which was maximal at a concentration of 2.5 to 5 jsM. This
effect of HgC12 was comparable to the effect of PMA (50 ng/ml) or MnC12
(500 .rM). T cell binding to FN induced by these stimuli could be totally
inhibited by an antibody against the f31 integrin subunit. FN binding
induced by HgCl2 and PMA, but not by MnCl2, was temperature
dependent. Furthermore, in contrast to the effect of MnCI2, the adhesion-
stimulatory effects of HgC12 and PMA turned out to be dependent on the
presence of extracellular Ca2 or Mg2*. Interestingly, when the cells were
preloaded with BAPTA-AM, an intracellular chelator of Ca2, induction
of adhesion by HgCI2 or PMA was prevented, whereas the effect of MnCl2
was not affected. These results indicate that HgCl2 is a potent activator of
integrin-mediated T cell binding to FN, which probably involves an
intracellular pathway. Activation of integrins by HgCl2 may play an
important role in activation and migration of leukocytes involved in
HgCl2-induced immune dysregulation in vivo.
Synergistic effect of IL-la, IFN-y and TNF-a on RANTES production
by human proximal tubular epithelial cells (PTEC) in vitro. J.G.M.
Deckers, S. W. van der Kooif L.A. van Es, Fl. van der Woud and MR.
Daha, Department of Nephrology, Leiden University Hospital, Leiden, The
Netherlands. In biopsies from renal transplant patients with rejection,
RANTES (Regulated upon Activation, Normal T cell Expressed and
Secreted) is detected in both infiltrating mononuclear cells and renal
tubular epithelium. The mechanisms involved in up-regulation of
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RANTES in tubular epithelium have not yet been resolved. In the present
study we investigated the production of RANTES, in the presence and
absence of various cytokincs, by human primary PTEC lines in vitro.
RANTES production was determined by ELISA (lower detection limit 3
pg/mI). No detectable RANTES was found in 72 hr culture supernatants
of 7 different PTEC lines when cultured in DMEM/HAMF12 under serum
free conditions. The presence of IL-la, IFN-y or TNF-a alone did not
result in significant induction of RANTES. However, a combination of
IFN-y together with IL-la or with TNF-cs resulted in a strong induction of
RANTES production (2046 817 and 2595 525 pg/ml, respectively) in
all PTEC lines. RANTES production after stimulation with a combination
of IL-la and TNF-a was less prominent (352 532 pg/mI) and only
detectable in 5 of 7 PTEC lines. The cytokine induced RANTES produc-
tion could be inhibited by cycloheximide indicating that de novo protein
synthesis is required for RANTES production. The induction of RANTES
by combinations of IL-la, IFN-y and TNF-a was both dose- and time-
dependent. Since the production of RANTES by PTEC is more pro-
nounced in the presence of T cell-derived IFN-y (in combination with
either IL-la or TNF-a), we hypothesize that RANTES produced by
PTEC presumably plays a prominent role in the amplification phase of the
immune response rather than in the initiation stage.
Hantaviruses, (HTV), lipids and cytokines. J. Clement, P. Heyman; P.
Colson; J. W.M. van der Meer, M. van Deuren, and P. Demacker, Military
Hospital, Bmssels, Belgium; C.S.F. Chimay, Belgium; Nijmegen University,
Nijmegen, The Netherlands. HTV can induce mild to life-threatening forms
of acute renal failure (ARF) and/or adult respiratory distress syndrome
(ARDS), the pathophysiology of which is ill understood. "HTV-nephrop-
athy" is characterized by strikingly few lesions on kidney biopsy, except for
interstitial edema and the triad ARF-proteinuria-thrombocytopenia.
These symptoms are always transient and self-remitting, suggesting a
functional disorder. During a 1993 epidemic in Belgium, we were struck by
unexplained collapses of serum cholesterol (S5,) and paradoxical in-
creases of fasting serum triglycerides (STO) levels. In a total of 58 patients
at the peak of the disease we found a significant (P < 0.001, paired t-test)
decrease of total (mean 141 91 mg%) and of serum HDL
cholesterol (mean 14 20 mg%), when compared to serum levels after
recovery, being 238 106 mg% for S601, respectively 52 32 mg% for
serum HDL cholesterol. Conversely, STG levels during disease rose
significantly higher (mean 329 298 mg%) than after recovery (mean
199 407 mg%). Serum lipid perturbations were most abnormal in severe
cases: the lowest (53 mg%), respectively the lowest SIIDL (5 mg %)
level was recorded each time in HTV-associated ARDS. Significant
correlations were also found between the degree of thrombocytopenia and
serum total cholesterol (r = 0.52, P < 0.001), respectively, serum HDL
cholesterol (r = 0.45, P < 0.01). Moreover, significant negative correla-
tions were demonstrated between and the serum levels of various
cytokine receptor or antagonists, that is, TNF R p55 (r =
—0.624), TNF R
p75 (r —0.711), IL-I RA (r = —t).601) and PLA2 (r = —0.456; allP <
0.001). High 5Th have been attributed to increased hcpatic lipogenesis,
together with decreased lipoprotein lipasc activity, both induced by
pro-inflammatory cytokines such as TNF-a, IL-l and IL-6. Low S1,0 and
low HDL may he linked in part to cytokine-induced reduction of hepatic
lipase. If confirmed in other HTV infections, serum lipid perturbations
could be used as an easy and quick way of assessing, and even of
predicting, clinical severity. Our findings furthermore suggest a pivotal
role of these cytokines in the pathophysiology of both ARF and ARDS.
Genetic susceptibility is more important than systemic blood pressure
in determining the development of renal damage after unilateral nephrec-
tomy (UNX) in rats. A.P. Provoo.s't, R.P.E. van Dokkum, and Hf. Jacob,
Department of Pediatric Suigery, Erasmus University, Rotterdam, the Neth-
erlands, and Department of Physiology, Genetics Laboratory, Medical Col-
lege of Wisconsin, Milwaukee, Wisconsin, USA. A reduced number of
nephrons has been implicated as an important factor in progressive renal
damage and hypertension. 1-lowever, genetic factors independent from
blood pressure also appear to determine the susceptibility to develop
progressive renal damage. To determine their relative contributions, we
have assessed the effects of UNX at young age on proteinuria (UV) and
systolic blood pressure (SBP) in various rat strains and Fl crosses differing
in basal SBP level. Experiments were carried out in hypertensive Strains
(SHR and FITH), normotensive strains (Fl-IL and ACT), and Fl crosses of
(SI-IR >< FFIH) and (SHR X Fl-IL) rats. A UNX was done at 4 to 5 weeks
of age. Age matched rats with 2 intact kidneys served as controls. The
levels of U,V (mg/day per 100 g body wt) and SBP (mm Hg) were
determined at 8 and 16 weeks after surgery. The results obtained at 16
weeks after UNX, that is, at the age of 21 weeks are presented.
Strain
Control UNX
SBP UV SBP UV
SHR 204 4 8.5 0.8 207 9 11,4 2.1
SHR x FHH 156 7 6.2 0.9 156 6 11.7 5.4
FHH 149 4 49.0 4.0 145 2 81.0 38.7
SHR x FHL 143 4 5.2 0.6 144 4 8.6 3.1
ACI 128 2 4.8 1.2 120 6 5.5 1.4
FHL 120 4 6.7 0.8 117 8 24.1 6.5
All data are mean SD.
Comparing the UNX and control rats clearly shows that UNX has no
significant effect on SBP obtained 16 weeks later. Genetic differences
determine the development of proteinuria after UNX. Both FH rat strains
develop significant U,V, the difference most likely to be due to a
difference in SBP. Susceptibility to induce renal damage appears a
recessive trait, since the U,V in the Fl crosses with SHR is significantly
reduced compared to the FH parent strains, despite the presence of higher
SBP levels. Although UNX and increased SBP may both contribute, they
are not sufficient to induce severe proteinuria in rats when genetic
susceptibility is absent.
Intradialyzer sequestration of polymorphonuclear cells (PMN). MPG.
Grooteman, A.J. van Houte, M. Schoorl, M.J. Nubé, Department of Haemo-
dialysis, Medical Center Alkmaar, Alkmaar, The Netherlands. Hemodialysis
(HD)-related bioincompatibility (BI) is generally studied in peripheral
blood (PB) samples, although BI originates inside the dialyzer. Therefore,
in order to analyze dialyzer-adherent cells, we developed a reliable elution
technique. In the present summary, combined data from several elution
studies are presented, in particular as far as intradialyzer PMN adhesion
is concerned. The following studies are included: (1) a eomparitive elution
study between three membranes, with different complement-activating
properties (CTA, PS, and CU), eluted after HD; (2) sequential elution
after 7½ (DE-7½) and 180 (DE-180) mm of HD of CTA membranes; (3)
comparison of eluates obtained after HD with heparin (HeHD) and
citrate (CiHD) anticoagulation. Blood samples were drawn before HD
(tO), at t7½ (study 2) and after HD (t180). In both PB and DE, WBC
count and differentiation were assessed, as well as the expression of PMN
adhesion markers (CD11b, CD62L). DE-180 contained 44 33 X 106
cells, consisting mainly of PMN (83%). Neither the type of membrane, nor
the mode of anticoagulation affected the number of eluted cells or WBC
differentiation. Only time appeared crucial: DE-7½ contained 3.0 3.7 X
106 WBC (P = 0.02 vs. DE-180). As for PMN adhesion markers, DE-7/2
and PB t7½ showed similar expression of CD11b, whereas an increase was
noted in DE-180, both after CiHD (168%, P < 0.01) and HeHD (121%,
NS) if compared with PB. CD62L expression was markedly lower in all
eluates (13 to 30%, P < 0.001), compared with PB. In conclusion,
relatively few cells, consisting mainly of PMN, adhere to the dialyzer. The
low cell counts in DE-7½ indicate that intradialyzer sequestration hardly
contributes to the early PB neutropenia, at least in the ease of CTA. Cell
numbers in DE-180 appeared not to be influenced by membrane type or
mode of anticoagulation, suggesting that neither complement nor Ca2 is
significantly involved. Lastly, since CD11b expression was similar in PB
and DE, intradialyzer PMN trapping seems not mediated by adhesion-
molecules, but possibly due to other factors, such as mechanical forces.
Renal hemodynamic effects of the angiotensin II receptor antagonist
candesartan in patients with impaired and normal renal function. H.
Buter, G. NavEs, D. de Zeeuw, and P.E. de Jong, Departments of Nephrology
and Clinical Pharmacology, University Hospital Groningen, Groningen, The
Netherlands. Angiotensin II receptor antagonists are a new class of
antihypertensives. Based on animal experiments and their antiproteinuric
effect in humans, a renal protective effect is likely. However, their effect on
renal hemodynamics in patients with impaired renal function is scarcely
documented. We therefore measured renal and systemic hemodynamics
after a single dose of candesartan 8 mg and after 5 days maintenance
treatment (8 mg o.i.d.) in hypertensive patients (diastolic blood pressure
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90 to 109 mm Hg) with renal function ranging from normal to severely
impaired. Time control data were obtained after administration of vehicle.
GFR and ERPF were measured as the clearances of '251-iothalamate and
1311-hippuran, respectively. Seventeen patients were included (4 with GFR
<30, 5 with GFR 30 to 60, and 8 with GFR > 60 mI/mm). Results
(median and 95% CI) are expressed as a percentage change. For the single
dose these changes are corrected for diurnal variations.
Maintenance
Pre-treatment Single dose % change
MAPmmHg 118(107to126)
ERPF mi/mm 256 (203 to 412) 13 (7 to 19)" 10 (3 to 14)"
GFR mi/mitt 60(49 to 94) 2 (—2 to 6) 0 (—7 to 2)
FF 0.23 (0.22to0.26) —11 (—14 to 5)"
—12(—l3to —4)"
RVR 24(15 to 47) —18 (—22 to —13)" —13 (—25 toO)"
dyne s
cm5
a P < 0.01 vs. pre-treatment, b P < 0.01 vs. baseline
Treatment with candesartan resulted in a fall in blood pressure. The rise
in ERPF and the fall in FF after a single dose was more pronounced in
patients with normal GFR as shown by the correlation between initial
GFR and percentage change in ERPF and FF (both P <0.05). These
results suggest that renal vasodilation was more pronounced in patients
with normal renal function. Interestingly, on maintenance treatment,
these correlations were absent, indicating that renal vasodilation occurs
then both in patients with normal and impaired renal function. No
correlations were found between changes in blood pressure and renal
hemodynamics. In conclusion, candesartan cilexitil induces renal vasodi-
lation during continued treatment. This can be achieved not only in
patients with normal renal function but also in patients with impaired
renal function.
Intravenous iron in dialysis patients: Adjust EPO dose? F.M. van der
Sande, E.C.M. van Pampus, KM.L. Leunissen, and J.N.M. Barendregt,
Department of Internal Medicine, Academic Hospital Maastricht, The Neth-
erlands. The optimal adjustment of recombinant erythropoietin (EPO)
dose after initiation of intravenous iron therapy (ivFe), to avoid progres-
sive anemia or polyglobulinemia, is unknown. We performed a prospective
randomized trial to study the possibility of reducing the EPO dose after
initiation of ivFe in relatively "iron deplete' dialysis patients (serum
ferritin < 100 mg/liter or transferrin saturation < 20%). After a run-in
period of 3 months, during which iron was administered orally (ferrosi
fumaras 0.2 g thrice daily), stable "iron deplete' patients were randomized
to receive 0%, 50% or 100% of their original weekly subcutaneous EPO
(Eprex, Jansen-Cilag) dose and intravenously 100 mg iron saccharate
(Venoferrum, Fresenius) bi-weekly during 3 months. Hematocrit (Hct),
ferritin (FER, mg/liter), transferrin Saturation (TRS, %) and need for
transfusion of packed erythrocytes or adjustment of EPO dose (TRANS,
% of group developing severe anemic symptoms and/or having a decline of
Hct larger than 0.12 or below 0.25) were measured at least at beginning
and end of each period. Pre-transfusion Hct values are reported in
transfused patients. During the run-in period the EPO-0% (N = 7), the
EPO-50% (N = 10) and the EPO-100% (N = 12) groups were similar
regarding age (68 9 years), time on dialysis (3.4 2.7years), EPO dose
(7.5 3.1 kU), Hct (0.33 0.05), FER (61 51), TRS (19 8%) and
TRANS (31%). After start of ivFe, FER increased by 120 16, P < 0.01
in all groups. TRS increased by 4.0 1.6% in the EPO-0% group and by
4.0 1.8% in the EPO-50% group, both P < 0.05, and remained
unchanged in the EPO-lOO% group. TRANS increased by 57% in the
EPO-0%, P < 0.05, remaining unchanged in the other groups. Hct
decreased by 0.04 0.01, P < 0.05 in the EPO-50% group. The study
indicates that replacement of ferrosi fumaras by intravenous iron sac-
charate in "iron deplete' hemodialysis patients increases FER and TRS.
Reduction of EPO dose at the start of ivFe is ill-advised because ii reduces
Hct values and increases the need for transfusions within the first 3
months.
Fracture incidence after kidney transplantation. R. de Sévaux, J. Wetzels
and A. Hoitsma, Department of Nephrology, University Hospital, Nzjmegen,
The Netherlands. Several long-term complications occur after successful
kidney transplantation. One of these is corticosteroid-induced osteoporo-
sis, resulting in fractures. Retrospectively we determined the fracture
incidence in our patients as follows: all patients with good graft function,
transplanted before Januaiy 1st, 1988, were sent a questionnaire and their
medical records were studied. We asked for the occurrence of fractures
after transplantation, the existence of osteoporosis and a possible therapy
for osteoporosis. A total of 292 patients were identified (165 men, 127
women). The mean age at transplantation for men was 35 years (range 4
to 69 years) and for women 36 years (range 5 to 61). Two hundred and
Sixteen questionnaires (74%) were returned, 284 medical records were
reviewed (98%). In this way we obtained data on 290 of 292 patients. The
mean duration of follow-up for men was 13 years (range 8 to 27 years) and
for women 14 years (range 8 to 25 years). Sixty-eight fractures occurred in
43 patients (17 men, 26 women); in most of the cases there was only a
minor or no trauma. Fractures were situated in leg/ankle/foot (25>< in 20
patients), arm/wrist/hand (23x in 16 patients), ribs (6x in 6 patients),
pelvis (2x in 2 patients), vertebrae (in 10 patients), sternum (lx) and
clavicle (IX). In half of the cases, the first fracture occurred within 5 years
after transplantation. Fractures occurred significantly more often in
women (P < 0.02). The time on dialysis before, and the cumulative dose
of corticosteroids in the first 3 months after transplantation did not differ
between man or women with or without a fracture. Women with one or
more fractures were transplanted at a significant older age (42 vs. 35 years;
P < 0.05) and were significantly older at the moment of follow-up than
women without fractures (55 vs. 48 years; P < 0.05); the duration of
follow-up was 14 years in both groups. Fractures were confirmed radio-
logically; in 19/43 patients signs of osteoporosis were seen on these
radiographs. In 9 of these 19 patients densitometry was performed; 8 of
them indeed had osteoporosis and were intermittently treated for osteo-
porosis. In the whole group of 292 patients, 28 were treated for osteopo-
rosis; 14 of them had fractures before this treatment. Our conclusions are:
15% of our patients experienced one or more fractures after kidney
transplantation and there is an apparent correlation with osteoporosis.
Prediction of overhydration in hemodialysis (HD) patients by measur-
ing blood pressure response to Valsalva maneuver. D.J. W. van Kraaif I.H.
Go, M.M.J. Schuurmans, R. W.M.M. Jansen, W.H.L. Hoefnagels, Depart-
ment of Internal Medicine, Canisius-Wilhelmina Hospital and Department of
Geriatric Medicine, University Hospital Nijmegen, Nijmegen, The Nether-
lands. Distinct correlations between the systolic blood pressure ratio
during a pressure-monitored Valsalva maneuver and pulmonary wedge
pressure have been demonstrated previously. We performed non-invasive
blood pressure measurements (FinapresR) during Valsalva maneuvers in
15 patients on chronic HD, and compared the use of this procedure in
identifying overhydrated HD patients with four other methods. During the
five-week study period, 5 patients experienced an episode of overhydra-
tion, necessitating medical intervention. Compared are predialysis means
of pre- vs. post-overhydration periods in 5 overhydrated patients (I), and
of 5 overhydrated patients vs. 10 controls (II).
Method
P valuesa
I (N 5) II (N = 15)
Blood pressure ratio during Valsalva
Composite clinical assessment seoreb
Weight deviation of target dry weight
Central venous pressure
Extracellular fluid volumec
0.025
0.05 1
0.121
0.355
1.000
0.032
0.006
0.436
0.159
0.327
Wileoxon rank sum test
h Composed by an experienced nephrologist, including evaluation of
thirst, dry mouth, dizziness, muscle cramps, decreased skin turgor, dys-
pnea, orthopnea, elevated central venous pressure, pulmonary rales and
edema
"Bio-eleetrical conductivity measurements
Only blood pressure ratios and clinical assessment scores correlated well
(r = 0.70, P 0.004) in all patients. In conclusion, assessment of the blood
pressure response to a Valsalva maneuver appears to be a useful addi-
tional tool to identify overhydrated HD patients and to evaluate the effect
of treatment interventions in such patients.
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Use of serum hemoglobin (Hb) versus serum albumin (Aib) concentra-
tions in estimating blood volume decrease during hemodialysis. D.J. W.
van Kraaij, M.MJ. Schuurmans, I.H. Go, R.W.M.M Jansen, WH.L.
Hoefnagels, Department of Internal Medicine, Canisius- Wilhelmina Hospital;
Department of Geriatric Medicine, University Hospital Nijmegen, Nijmegen,
the Netherlands. Appropriate assessment of circulating blood volume is
critical in the management of patients on hemodialysis (HD). Increments
in both serum albumin (Alb) and hemoglobin (Hb) concentrations during
HD have been used previously to estimate circulating blood volume
changes and predict hypotensive episodes. We compared pre- and post-
dialytic serum concentrations of Hb and Alb, and their mutual correlation
in 15 HD patients on five separate occasions. Changes in concentrations
are expressed as percentage of predialysis values.
Dutch population (148/100,000). The mean age of patients with this type
of fracture was 62.7 year, compared to 77.6 in the control population.
Seven were treated with immobilization only, and in one of them a
complication (infection) occurred. Fourteen fractures were operated, 2
patients died in the postoperative period (myocardial infarction, sepsis
after infection of the prosthesis), in 4 cases healing was complicated
(pseudoarthrosis, refracturated, infection, thrombosis). In 367 renal trans-
plant patients we found 24 fractures. The total incidence was 978/100,000
fracture/patient year. Fourteen were treated by immobilization only, all
healed without delay or complications. Ten fractures were operated, in
one the consolidation was delayed. From our data we conclude that the
incidence of fractures of the hip is increased in dialysis and renal
transplant patients. The incidence of complications appears to be normal.
% (N = 15)
Alb 9.7 2.3
zXHb 7.8 1.9
Alb — zXHb 1.9 0.8 (95% CI: 0.2_3.6)a
(iAlb — Hb)/Alb 34.7 9.3(95% CI: —9.4—+ 112.1)
Data are mean SEM. ' P < 0.05 (Wilcoxon signed rank test)
There was a significant mean difference of estimated blood volume
decrease during HD using AIb versus Hb concentration measurements
(Alb — zHb). This difference was on average 35% of the Aib-estimated
blood volume decrease with a wide 95% CI of —9% to + 112% (Alb —
Hb)/A1b). Various possible explanations for this difference include
capillary leakage of AIb, intravascular pooling of Hb, and measurement
inaccuracy. However, procentual changes in Aib and Hb concentrations
correlated well (r = 0.8857, P < 0.001). The reliability of both methods
remains questionable without comparison to an accurate standard mea-
surement.
Fractures of long bones in dialysis and renal transplant patients:
Incidence and complication rate. M.J. Wiezer, M.H.J.L. Pannekoek,
I.A.J.M Broeders, R.i Hené, and Chr. van der Werken, Departments of
Surgery and Nefrology, University Hospital Utrecht and Stichting Thuisdial-
yse, Midden Nederland (STD), the Netherlands. Renal osteodystrophy and
corticosteroid induced osteoporosis may affect the quality of bone in
patients on renal replacement treatment. This might cause an increase in
the incidence of long bone fractures as well as delayed healing. Therefore,
we investigated the cause, localization and the complication rate of
fractures in all patients who were treated with hemodialysis or had a
functional renal transplant between January 1986 and December 1995 in
our hospital. All patient records were investigated, and the living patients
were interviewed by telephone or by mail. In 19 of the 629 hemodialysis
patients we found 21 fractures. The total incidence of fractures was
951/100,000 fractures/patient year. For the fractures of the collum femoris
this incidence was 498/100,000, being higher than the incidence of the
Effects of low dose nifedipine on urinary protein excretion (UPE) rate
in patients with renal disease. H.i Kloke, J.F.M. Wetzels, RAP. Koene,
and F. TM. Huysmans, Department of Nephrology, University Hospital,
Nijmegen, The Netherlands. The reported effects of calcium channel
blockers on UPE are quite equivocal. It has been suggested that the
short-acting dihydropyridine calcium channel blocker, nifedipine, in-
creases UPE by interference with tubular protein reabsorption. In a
randomized controlled trial, ten patients with renal disease (UPE 5.0
1.1 g/day, mean suM) were treated with a dose of 10 mg nifedipine o.d.
during one week. The acute effects on renal and systemic hemodynamics
and on urinary albumin, IgG and f32-microglobulin (f32m) excretion were
investigated during a clearance study in supine position after the first dose.
After one week of treatment UPE rates were measured in 24-hour urine
samples collected ambulatory in consecutive fractions of four to eight
hours during normal daily activities. After the first dose nifedipine lowered
mean arterial blood pressure in supine position by 7 1 mm Hg (P <
0.01), attenuated proximal tubular sodium reabsorption [fractional excre-
tion (FE) of sodium 3.48 0.49 vs. 2.62 0.35% during control, P <
0.02], but did not affect proximal tubular protein reabsorption (FE of 132m
0.97 0.30 vs. 0.98 0.32% during control, NS). The decrease in blood
pressure was not accompanied by decreases in urinary albumin or IgG
excretion rates. The selectivity index as well as GFR, RPF and filtration
fraction did not change. Continued treatment for one week with nifedipine
did not influence 24 hour UPE. However, we observed an effect when
comparing the urine collected during daily activities in the first four hours
after drug intake with the urine collected at the start of the study when
supine. During control measurements there was a slight increase in UPE.
During nifedipine the increase in albuminuria was more marked and
correlated with the selectivity index (r =
—0.82, P < 0.01). In conclusion:
(1.) nifedipine 10 mg orally did not impair tubular protein reabsorption;(2.) nifedipine had no immediate antiproteinuric effect despite the ob-
served blood pressure reduction; and (3.) nifedipine increased UPE in
ambulatory urine collections. This latter observation might explain the
seemingly different effects of dihydropyridine calcium channel blockers as
reported in previous studies.
